TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NovoCure ( (NVCR) ) has issued an announcement.
On November 24, 2025, Ashley Cordova resigned as CEO and Director of Novocure, effective November 30, 2025, with no disagreements reported. Frank Leonard, previously the company’s President, was appointed as the new CEO effective December 1, 2025. Leonard, who has been with Novocure since 2010, has played a significant role in the company’s operations and strategy, and his appointment is expected to guide the company through future transformative milestones.
The most recent analyst rating on (NVCR) stock is a Sell with a $11.50 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.
Spark’s Take on NVCR Stock
According to Spark, TipRanks’ AI Analyst, NVCR is a Underperform.
NovoCure’s overall stock score is primarily impacted by its financial challenges and weak technical indicators. The company’s high leverage and negative cash flows, combined with bearish market momentum, contribute to a low score. Valuation concerns further weigh down the score, as the negative P/E ratio and lack of dividend yield make it less attractive to investors.
To see Spark’s full report on NVCR stock, click here.
More about NovoCure
Novocure is a global oncology company focused on extending survival in aggressive forms of cancer through its innovative Tumor Treating Fields therapy. The company’s products are approved for treating glioblastoma, non-small cell lung cancer, and malignant pleural mesothelioma, with ongoing clinical trials exploring additional applications. Novocure’s global headquarters is in Baar, Switzerland, with U.S. headquarters in Portsmouth, New Hampshire, and R&D facilities in Haifa, Israel.
Average Trading Volume: 1,623,698
Technical Sentiment Signal: Sell
Current Market Cap: $1.43B
See more data about NVCR stock on TipRanks’ Stock Analysis page.